Alaunos Therapeutics, Inc. is a preclinical-stage biopharmaceutical company developing novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, including MASLD (fatty liver disease). Its lead candidate, ALN1003, uses a non-hormonal, non-incretin mechanism of action. The company previously developed adoptive TCR-T cell therapies for oncology. It has not generated product revenue and reported a net loss of $4.2 million for the year ended December 31, 2025, with an accumulated deficit of $924.6 million.
Q2 FY2026 — expected 2026-08-14
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-31 | 2025-12-31 | 0001193125-26-134720 | EDGAR | 47K words |
| 2025-03-31 | 2024-12-31 | 0000950170-25-047758 | EDGAR | — |
| 2024-04-01 | 2023-12-31 | 0000950170-24-038868 | EDGAR | — |
| 2023-03-07 | 2022-12-31 | 0000950170-23-006377 | EDGAR | — |
| 2022-03-30 | 2021-12-31 | 0000950170-22-004972 | EDGAR | — |
| 2021-03-01 | 2020-12-31 | 0001193125-21-063387 | EDGAR | — |
| 2020-03-02 | 2019-12-31 | 0001193125-20-058863 | EDGAR | — |
| 2019-03-05 | 2018-12-31 | 0001193125-19-063978 | EDGAR | — |
| 2018-03-01 | 2017-12-31 | 0001193125-18-067077 | EDGAR | — |
| 2017-02-16 | 2016-12-31 | 0001193125-17-046668 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-14 | 2025-09-30 | 0001193125-25-282988 | EDGAR | 18K words |
| 2025-08-14 | 2025-06-30 | 0000950170-25-108887 | EDGAR | — |
| 2025-05-15 | 2025-03-31 | 0000950170-25-072709 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0000950170-24-126793 | EDGAR | — |
| 2024-08-14 | 2024-06-30 | 0000950170-24-097142 | EDGAR | — |
| 2024-05-15 | 2024-03-31 | 0000950170-24-060075 | EDGAR | — |
| 2023-11-14 | 2023-09-30 | 0000950170-23-063354 | EDGAR | — |
| 2023-08-14 | 2023-06-30 | 0000950170-23-042486 | EDGAR | — |
| 2023-05-10 | 2023-03-31 | 0000950170-23-020088 | EDGAR | — |
| 2022-11-14 | 2022-09-30 | 0000950170-22-024695 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0000950170-22-017225 | EDGAR | — |
| 2022-05-16 | 2022-03-31 | 0000950170-22-009942 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-02 | 0001193125-26-084084 | EDGAR | 1K words |
| 2026-01-08 | 0001193125-26-007054 | EDGAR | — |
| 2025-12-23 | 0001193125-25-331147 | EDGAR | — |
| 2025-08-20 | 0000950170-25-110484 | EDGAR | — |
| 2025-07-22 | 0000950170-25-097591 | EDGAR | — |
| 2025-07-17 | 0000950170-25-096656 | EDGAR | — |
| 2025-07-10 | 0000950170-25-095029 | EDGAR | — |
| 2025-07-02 | 0000950170-25-093263 | EDGAR | — |
| 2025-06-26 | 0000950170-25-090202 | EDGAR | — |
| 2025-06-26 | 0000950170-25-090201 | EDGAR | — |
419 total filings indexed. 387 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001107421 |
| Ticker | TCRT |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.alaunos.com |
| Listed | 2005-08-24 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report